Encoded Therapeutics raises $275M Series F
Encoded Therapeutics raised $275 million in Series F financing co-led by GV and an undisclosed healthcare fund.
Backers include Braidwell, Matrix Capital Management, Nolan Capital, RTW Investments, Janus Henderson Investors, ARCH Venture Partners, Invus, SoftBank Vision Fund 2, Illumina Ventures, Farallon Capital Management and Venrock.
The financing supports pivotal ETX101 development for young children with SCN1A-positive Dravet syndrome, study expansion up to age 18 and internal GMP manufacturing. It also advances ETX301 toward a planned 2027 IND submission for post-amputation neuroma pain.
Use of funds
Support pivotal ETX101 study in young children with SCN1A+ Dravet syndrome
Expand ETX101 study to patients up to 18
Scale internal GMP manufacturing
Advance ETX301 toward 2027 IND submission for post-amputation neuroma pain